Michael Dolton

2.4k total citations · 1 hit paper
40 papers, 1.4k citations indexed

About

Michael Dolton is a scholar working on Pharmacology, Infectious Diseases and Physiology. According to data from OpenAlex, Michael Dolton has authored 40 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 11 papers in Infectious Diseases and 9 papers in Physiology. Recurrent topics in Michael Dolton's work include Antifungal resistance and susceptibility (9 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Drug Solubulity and Delivery Systems (5 papers). Michael Dolton is often cited by papers focused on Antifungal resistance and susceptibility (9 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Drug Solubulity and Delivery Systems (5 papers). Michael Dolton collaborates with scholars based in United States, Australia and France. Michael Dolton's co-authors include Andrew J. McLachlan, John E. Ray, Lisa Pont, Sharon C.-A. Chen, Kingsley Ng, Deborah Marriott, Dorothy Cheung, David F. Choy, Basil D. Roufogalis and David M. Burger and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Antimicrobial Agents and Chemotherapy and Annals of the Rheumatic Diseases.

In The Last Decade

Michael Dolton

37 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial

2021 195 citations Steven G. Kelsen, Ioana Agache et al. Journal of Allergy and Clinical Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Dolton United States	16	805	589	335	245	180	40	1.4k
Lambert F. R. Span Netherlands	20	708 0.9×	675 1.1×	185 0.6×	60 0.2×	141 0.8×	45	1.4k
Eliane M. Billaud France	23	747 0.9×	646 1.1×	264 0.8×	81 0.3×	56 0.3×	69	2.0k
Lynn Purkins United Kingdom	16	889 1.1×	579 1.0×	294 0.9×	80 0.3×	85 0.5×	21	1.4k
So–Youn Shin South Korea	24	242 0.3×	624 1.1×	97 0.3×	135 0.6×	127 0.7×	73	1.8k
H Laufen Germany	22	365 0.5×	470 0.8×	325 1.0×	125 0.5×	81 0.5×	76	1.5k
Marieke G. G. Sturkenboom Netherlands	20	610 0.8×	511 0.9×	362 1.1×	55 0.2×	167 0.9×	49	1.1k
Nkechi Azie United States	27	1.9k 2.4×	1.6k 2.7×	240 0.7×	66 0.3×	50 0.3×	57	2.5k
Carsten Müller Germany	23	519 0.6×	455 0.8×	197 0.6×	47 0.2×	77 0.4×	101	1.7k
Donghui Yu China	21	375 0.5×	391 0.7×	92 0.3×	66 0.3×	49 0.3×	37	1.2k
Guy Aymard France	18	361 0.4×	256 0.4×	164 0.5×	44 0.2×	118 0.7×	35	1.5k

Countries citing papers authored by Michael Dolton

Since Specialization

Citations

This map shows the geographic impact of Michael Dolton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Dolton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Dolton more than expected).

Fields of papers citing papers by Michael Dolton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Dolton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Dolton. The network helps show where Michael Dolton may publish in the future.

Co-authorship network of co-authors of Michael Dolton

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Dolton. A scholar is included among the top collaborators of Michael Dolton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Dolton. Michael Dolton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bittner, Beate, Javier Muñoz, Sabine Frank, et al.. (2025). Clinical Qualification of Subcutaneous Injection Devices for Monoclonal Antibodies. BioDrugs. 40(1). 5–21.

Schauer, Stephen, Balázs István Tóth, Julie Lee, et al.. (2024). Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology. Alzheimer s & Dementia. 20(12). 8855–8866. 7 indexed citations

Bowman, Christine M., Michael Dolton, Fang Ma, et al.. (2024). Understanding CYP3A4 and P-GP mediated drug-drug interactions through PBPK modeling - case example of pralsetinib. Drug Metabolism and Pharmacokinetics. 55. 100969–100969. 2 indexed citations

Dolton, Michael, Christine Bowman, Sravanthi Cheeti, et al.. (2024). Integrating Dynamic in vitro Systems and Mechanistic Absorption Modeling: Case Study of Pralsetinib. Journal of Pharmaceutical Sciences. 113(9). 2952–2956.

Veerabathiran, Ramakrishnan, Brendan C. Bender, Jurgen Langenhorst, et al.. (2024). Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies. The Journal of Prevention of Alzheimer s Disease. 11(5). 1241–1250. 3 indexed citations

Jamalian, Samira, Michael Dolton, Pascal Chanu, et al.. (2023). Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB. CPT Pharmacometrics & Systems Pharmacology. 12(7). 1029–1042. 10 indexed citations

Park, Hyunjin, et al.. (2023). Belvarafenib penetrates the BBB and shows potent antitumor activity in a murine melanoma brain metastasis model. Clinical & Experimental Metastasis. 40(2). 137–148. 5 indexed citations

Kesisoglou, Filippos, Sumit Basu, Stephanie Dodd, et al.. (2023). Streamlining Food Effect Assessment — Are Repeated Food Effect Studies Needed? An IQ Analysis. The AAPS Journal. 25(4). 60–60. 9 indexed citations

Chiang, Po‐Chang, Michael Dolton, Karthik Nagapudi, & Jia Liu. (2023). Exploring the Use of a Kinetic pH Calculation to Correct the ACAT Model with a Single Stomach Compartment Setting: Impact of Stomach Setting on Food Effect Prediction for Basic Compounds. Journal of Pharmaceutical Sciences. 112(7). 1888–1896. 1 indexed citations

10.

Maurer, Marcus, Dorothy Cheung, Xiaoying Yang, et al.. (2022). Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis. Journal of Allergy and Clinical Immunology. 150(6). 1517–1524. 43 indexed citations

11.

Chiang, Po‐Chang, Jia Liu, Karthik Nagapudi, et al.. (2022). Elucidating a Potential Mechanism of Permeability Enhancer Sodium N-[8-(2-hydroxybenzoyl) amino] Caprylate in Rats: Evidence of Lymphatic Absorption of Cyanocobalamin using the Mesenteric Lymph Duct Cannulated Rat. Journal of Pharmaceutical Sciences. 111(12). 3417–3423. 2 indexed citations

12.

Kelsen, Steven G., Ioana Agache, Weily Soong, et al.. (2021). Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. Journal of Allergy and Clinical Immunology. 148(3). 790–798. 195 indexed citations breakdown →

13.

Liu, Jia, Karthik Nagapudi, Michael Dolton, & Po‐Chang Chiang. (2021). Utilizing Tiny-TIM to Assess the Effect of Acid-Reducing Agents on the Absorption of Orally Administered Drugs. Journal of Pharmaceutical Sciences. 110(8). 3020–3026. 10 indexed citations

14.

Guthrie, Heather, Lawrence S. Honig, Helen Lin, et al.. (2020). Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks. Journal of Alzheimer s Disease. 76(3). 967–979. 41 indexed citations

15.

Dolton, Michael, Po‐Chang Chiang, Fang Ma, Jin Y. Jin, & Yuan Chen. (2020). A Physiologically Based Pharmacokinetic Model of Vismodegib: Deconvoluting the Impact of Saturable Plasma Protein Binding, pH-Dependent Solubility and Nonsink Permeation. The AAPS Journal. 22(5). 117–117. 6 indexed citations

16.

Colin, Pieter, Karel Allegaert, Alison H. Thomson, et al.. (2019). Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations. Clinical Pharmacokinetics. 58(6). 767–780. 67 indexed citations

17.

Dolton, Michael, Roger J. M. Brüggemann, David M. Burger, & Andrew J. McLachlan. (2014). Understanding Variability in Posaconazole Exposure Using an Integrated Population Pharmacokinetic Analysis. Antimicrobial Agents and Chemotherapy. 58(11). 6879–6885. 66 indexed citations

18.

Dolton, Michael & Andrew J. McLachlan. (2014). Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections. Current Opinion in Infectious Diseases. 27(6). 493–500. 21 indexed citations

19.

Dolton, Michael, et al.. (2014). Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. Journal of Antimicrobial Chemotherapy. 69(6). 1633–1641. 78 indexed citations

20.

Dolton, Michael, Vidya Perera, Lisa Pont, & Andrew J. McLachlan. (2013). Terbinafine in Combination with Other Antifungal Agents for Treatment of Resistant or Refractory Mycoses: Investigating Optimal Dosing Regimens Using a Physiologically Based Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy. 58(1). 48–54. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact